These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 39088160)

  • 1. Clinical and laboratory remission with rituximab in anti-MuSK-positive myasthenia gravis.
    Inan B; Orhan IG; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
    Ir J Med Sci; 2024 Aug; ():. PubMed ID: 39088160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Low-Dose Rituximab in Anti-MuSK Myasthenia Gravis Patients: A Retrospective Study.
    Meng X; Zeng Z; Wang Y; Guo S; Wang C; Wang B; Guo S
    Neuropsychiatr Dis Treat; 2022; 18():953-964. PubMed ID: 35535211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
    Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
    Front Immunol; 2020; 11():613. PubMed ID: 32431692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study.
    Zhao S; Zhang K; Ren K; Lu J; Ma C; Zhao C; Li Z; Guo J
    BMC Neurol; 2021 Nov; 21(1):428. PubMed ID: 34732168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
    Hehir MK; Hobson-Webb LD; Benatar M; Barnett C; Silvestri NJ; Howard JF; Howard D; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; LaBoy SM; Fellman MA; Greene SM; Pasnoor M; Burns TM
    Neurology; 2017 Sep; 89(10):1069-1077. PubMed ID: 28801338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.
    Topakian R; Zimprich F; Iglseder S; Embacher N; Guger M; Stieglbauer K; Langenscheidt D; Rath J; Quasthoff S; Simschitz P; Wanschitz J; Windisch D; Müller P; Oel D; Schustereder G; Einsiedler S; Eggers C; Löscher W
    J Neurol; 2019 Mar; 266(3):699-706. PubMed ID: 30649616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising efficacy of Low-Dose rituximab in Muscle specific kinase antibody positive Myasthenia Gravis.
    Yang X; Zhang W; Chang X; Li Z; Du R; Guo J
    Neurosci Lett; 2024 Jan; 818():137561. PubMed ID: 37984485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of rituximab on prognosis in myasthenia gravis: A single-center experience from Turkey].
    Göl MF; Kara F; Boz M; Mutlu A; Karakullukçu S; Boz C
    Ideggyogy Sz; 2022 Sep; 75(9-10):351-359. PubMed ID: 36218113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rituximab for the treatment of generalised myasthenia gravis: experience in clinical practice].
    Martínez-Monte E; Gascón-Giménez F; Domínguez-Morán JA; Láinez-Andres JM
    Rev Neurol; 2021 Nov; 73(12):416-420. PubMed ID: 34877644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective study of the safety and efficacy of rituximab in Iranian patients with myasthenia gravis: A single-center experience.
    Ziaadini B; Karimi N; Panahi A; Okhovat AA; Fatehi F; Nafissi S
    Curr J Neurol; 2022 Apr; 21(2):91-97. PubMed ID: 38011443
    [No Abstract]   [Full Text] [Related]  

  • 11. Rituximab in Myasthenia Gravis- Experience from a Low- and Middle-Income Country (LMIC) Setting.
    Shivaram S; Nagappa M; Varghese N; Seshagiri DV; Duble S; Siddappa SA; Hesarur N; Sinha S; Taly AB
    Neurol India; 2022; 70(5):1931-1941. PubMed ID: 36352590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis.
    Bastakoti S; Kunwar S; Poudel S; Quinonez J; Bista S; Singh N; Jha V; Ruxmohan S; Paesani S; Cueva W; Michel J
    Cureus; 2021 Nov; 13(11):e19416. PubMed ID: 34909332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study.
    Singh N; Goyal V
    J Neurol; 2019 Jul; 266(7):1596-1600. PubMed ID: 30919039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab treatment of myasthenia gravis: A systematic review.
    Tandan R; Hehir MK; Waheed W; Howard DB
    Muscle Nerve; 2017 Aug; 56(2):185-196. PubMed ID: 28164324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use and monitoring of low dose rituximab in myasthenia gravis.
    Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study.
    Dos Santos A; Noury JB; Genestet S; Nadaj-Pakleza A; Cassereau J; Baron C; Videt D; Michel L; Pereon Y; Wiertlewski S; Magot A
    Eur J Neurol; 2020 Nov; 27(11):2277-2285. PubMed ID: 32526053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation between clinical manifestation, prognosis and antibody in anti-muscle-specific tyrosine kinase antibody positive myasthenia gravis].
    Tan Y; Zhu L; Huang YY; Shi JY; Li J; Li K; Guan YZ; Cui LY
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(31):2433-2437. PubMed ID: 34399555
    [No Abstract]   [Full Text] [Related]  

  • 18. Spotlight on MuSK positive myasthenia gravis: clinical characteristics, treatment and outcomes.
    Huang Q; Li F; Zhao S
    BMC Neurol; 2022 Mar; 22(1):73. PubMed ID: 35246057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.
    Clifford KM; Hobson-Webb LD; Benatar M; Burns TM; Barnett C; Silvestri NJ; Howard JF; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; Laboy SM; Fellman MA; Howard DB; Kolb NA; Greene SM; Pasnoor M; Dimachkie MM; Barohn RJ; Hehir MK
    Muscle Nerve; 2019 Apr; 59(4):404-410. PubMed ID: 30575980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study.
    Litchman T; Roy B; Kumar A; Sharma A; Njike V; Nowak RJ
    J Neurol Sci; 2020 Apr; 411():116690. PubMed ID: 32028072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.